Takeaway

• In a large population-based study, both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) were associated with lower risk for severe COPD exacerbations among people with both type 2 diabetes and COPD compared with sulphonylureas.
• Dipeptidyl peptidase-4 inhibitors (DPP4is) had a minimal effect.

Why this matters

• Laboratory findings suggest that the...